These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1992 related articles for article (PubMed ID: 20130576)

  • 1. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
    Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
    Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
    Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug discovery: inhibitors that activate.
    Cichowski K; Jänne PA
    Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552
    [No Abstract]   [Full Text] [Related]  

  • 4. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
    Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
    Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
    Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
    Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
    Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
    Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
    Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.
    Hu J; Yu H; Kornev AP; Zhao J; Filbert EL; Taylor SS; Shaw AS
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6067-72. PubMed ID: 21441104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
    Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
    Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
    Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
    Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK and RAF inhibitors for BRAF-mutated cancers.
    Belden S; Flaherty KT
    Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
    Yao Z; Yaeger R; Rodrik-Outmezguine VS; Tao A; Torres NM; Chang MT; Drosten M; Zhao H; Cecchi F; Hembrough T; Michels J; Baumert H; Miles L; Campbell NM; de Stanchina E; Solit DB; Barbacid M; Taylor BS; Rosen N
    Nature; 2017 Aug; 548(7666):234-238. PubMed ID: 28783719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
    Nichols RJ; Haderk F; Stahlhut C; Schulze CJ; Hemmati G; Wildes D; Tzitzilonis C; Mordec K; Marquez A; Romero J; Hsieh T; Zaman A; Olivas V; McCoach C; Blakely CM; Wang Z; Kiss G; Koltun ES; Gill AL; Singh M; Goldsmith MA; Smith JAM; Bivona TG
    Nat Cell Biol; 2018 Sep; 20(9):1064-1073. PubMed ID: 30104724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.